All In Biotech

Drug Trial Radar · NCT07603401

Expanded Access Program of Bitopertin For Participants With EPP or XLP

Expanded Access Program Protocol: Bitopertin (DISC-1459) For The Treatment of Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP)

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Available

Status

Available

Enrollment

Not stated

Start

Not stated

Primary completion

Not stated

Sponsor

Lead sponsor
Disc Medicine, IncIndustry
Sponsor type
Industry
First posted
May 22, 2026

More drug trials from this sponsor

Design

Study type
Expanded access
Who can join
All sexes, from 12 years

Summary

As written by the sponsor on the registry.

The goal of this expanded access program is to provide bitopertin to patients with EPP and XLP who have no satisfactory treatment options available in the US and to learn if bitopertin is safe to treat EPP and XLP.

Conditions

  • Erythropoietic Protoporphyria (EPP)
  • X-Linked Protoporphyria (XLP)

Interventions

  • DISC-1459Drug

    DISC-1459, 60 mg oral dose once a day

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • University of Miami Miller School of Medicine

    Miami, Florida · Available

  • Massachusetts General Hospital

    Boston, Massachusetts · Available

  • MetroBoston Clinical Partners

    Boston, Massachusetts · Available

  • Henry Ford Health

    Detroit, Michigan · Available

  • Mount Sinai Hospital

    New York, New York · Available

  • Wake Forest University

    Winston-Salem, North Carolina · Available

  • The Cleveland Clinic Foundation

    Cleveland, Ohio · Available

  • The University of Texas Health Science Center at Houston

    Houston, Texas · Available

  • University of Washington

    Seattle, Washington · Available

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.